Theriva Biologics, Inc. financial data

Symbol
TOVX on NYSE
Location
9605 Medical Center Drive, Suite 270, Rockville, MD
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 11, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 178 % -51.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 9.6M shares -61.8%
Common Stock, Shares, Outstanding 9.06M shares -59.5%
Entity Public Float 5.3M USD
Common Stock, Value, Issued 8K USD -65.2%
Weighted Average Number of Shares Outstanding, Basic 6.75M shares +771%
Weighted Average Number of Shares Outstanding, Diluted 6.75M shares +771%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 10.5M USD -27.9%
General and Administrative Expense 16.6M USD +195%
Operating Income (Loss) -30M USD -23.5%
Nonoperating Income (Expense) 461K USD -57.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -29.6M USD -27.3%
Income Tax Expense (Benefit) -1.64M USD -15.1%
Net Income (Loss) Attributable to Parent -3.3M USD +26.4%
Earnings Per Share, Basic -4 USD/shares +90.8%
Earnings Per Share, Diluted -4 USD/shares +90.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 12.1M USD -27%
Assets, Current 14.7M USD -25.2%
Property, Plant and Equipment, Net 258K USD -23.2%
Operating Lease, Right-of-Use Asset 1.08M USD -29.1%
Intangible Assets, Net (Excluding Goodwill) 19.6M USD +2.32%
Goodwill 0 USD -100%
Assets 35.8M USD -15.5%
Accounts Payable, Current 607K USD -35.1%
Employee-related Liabilities, Current 759K USD -21.7%
Accrued Liabilities, Current 9.02M USD +158%
Contract with Customer, Liability, Current 906K USD
Liabilities, Current 12.4M USD +81%
Contract with Customer, Liability, Noncurrent 906K USD
Deferred Income Tax Liabilities, Net 413K USD -79.2%
Operating Lease, Liability, Noncurrent 584K USD -49.7%
Liabilities 25.2M USD +71%
Accumulated Other Comprehensive Income (Loss), Net of Tax 793K USD
Retained Earnings (Accumulated Deficit) -352M USD -9.16%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 10.6M USD -59%
Liabilities and Equity 35.8M USD -15.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.76M USD +2.56%
Net Cash Provided by (Used in) Financing Activities 3.07M USD
Net Cash Provided by (Used in) Investing Activities -8K USD +99.8%
Common Stock, Shares Authorized 350M shares 0%
Common Stock, Shares, Issued 9.09M shares -60.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.59M USD +67.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12.2M USD -27.1%
Deferred Tax Assets, Valuation Allowance 11.3M USD -60.1%
Deferred Tax Assets, Gross 15.7M USD -52.9%
Operating Lease, Liability 1.2M USD -28.6%
Payments to Acquire Property, Plant, and Equipment 8K USD
Lessee, Operating Lease, Liability, to be Paid 1.31M USD -33%
Property, Plant and Equipment, Gross 1.28M USD +5.08%
Operating Lease, Liability, Current 612K USD +19.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 369K USD -37.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 598K USD -10.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 115K USD -59.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 368K USD -36.8%
Deferred Tax Assets, Operating Loss Carryforwards 9.71M USD -64.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Lessee, Operating Lease, Liability, to be Paid, Year Four 368K USD +3.08%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 26K USD -33.3%
Deferred Tax Assets, Net of Valuation Allowance 4.38M USD -12.2%